MA29541B1 - Composes benzimidazole-carboxamide utilises comme agonistes du recepteur 5-ht4 - Google Patents

Composes benzimidazole-carboxamide utilises comme agonistes du recepteur 5-ht4

Info

Publication number
MA29541B1
MA29541B1 MA30466A MA30466A MA29541B1 MA 29541 B1 MA29541 B1 MA 29541B1 MA 30466 A MA30466 A MA 30466A MA 30466 A MA30466 A MA 30466A MA 29541 B1 MA29541 B1 MA 29541B1
Authority
MA
Morocco
Prior art keywords
compounds
receptor agonists
carboxamide compounds
benzimidazole carboxamide
formula
Prior art date
Application number
MA30466A
Other languages
English (en)
Inventor
Robert Murray Mckinnell
Roland Gendron
Lan Jiang
Seok-Ki Choi
Daniel D Long
Paul R Fatheree
Daniel Marquess
Sean M Dalziel
Kirsten M Phizackerley
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29541(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MA29541B1 publication Critical patent/MA29541B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS AGONISTES DU RÉCEPTEUR 5-HT4T BENZIMIDAZOLE-CARBOXAMIDE REPRÉSENTÉS PAR LA FORMULE (I), DANS LAQUELLE R1 ET X SONT TELS QUE DÉFINIS DANS LES SPÉCIFICATIONS OU UN SEL, UN SOLVANT OU UN STÉRÉOISOMÈRE DE CEUX-CI RÉPONDANT AUX NORMES PHARMACEUTIQUES. CETTE INVENTION CONCERNE AUSSI DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT CES COMPOSÉS, DES PROCÉDÉS D'UTILISATION DE CES COMPOSÉS POUR TRAITER DES MALADIES ASSOCIÉES À L'ACTIVITÉ DU RÉCEPTEUR5-HT4 ET, DES PROCESSUS ET DES INTERMÉDIAIRES QUI CONVIENNENT POUR PRÉPARER CES COMPOSÉS. CETTE INVENTION CONCERNE AUSSI DES FORMES CRISTALLINES D'UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE (I).
MA30466A 2005-05-25 2007-12-10 Composes benzimidazole-carboxamide utilises comme agonistes du recepteur 5-ht4 MA29541B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68447805P 2005-05-25 2005-05-25
US68446605P 2005-05-25 2005-05-25
US74841505P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
MA29541B1 true MA29541B1 (fr) 2008-06-02

Family

ID=37452788

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30466A MA29541B1 (fr) 2005-05-25 2007-12-10 Composes benzimidazole-carboxamide utilises comme agonistes du recepteur 5-ht4

Country Status (27)

Country Link
US (10) US8143279B2 (fr)
EP (1) EP1899324B1 (fr)
JP (2) JP5072111B2 (fr)
KR (1) KR101333280B1 (fr)
AR (1) AR057327A1 (fr)
AT (1) ATE535523T1 (fr)
AU (1) AU2006250009B2 (fr)
BR (1) BRPI0611202C1 (fr)
CA (1) CA2607280C (fr)
CY (1) CY1112366T1 (fr)
DK (1) DK1899324T3 (fr)
EA (1) EA013240B1 (fr)
ES (1) ES2376115T3 (fr)
HK (1) HK1110980A1 (fr)
HR (1) HRP20120108T2 (fr)
IL (1) IL186883A (fr)
MA (1) MA29541B1 (fr)
MX (1) MX2007014762A (fr)
MY (1) MY147756A (fr)
NO (1) NO339658B1 (fr)
NZ (1) NZ563068A (fr)
PE (1) PE20061446A1 (fr)
PL (1) PL1899324T3 (fr)
PT (1) PT1899324E (fr)
SI (1) SI1899324T1 (fr)
TW (1) TWI388555B (fr)
WO (1) WO2006127815A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1664036T3 (pl) * 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2410857B1 (fr) * 2009-03-23 2014-01-29 Merck Sharp & Dohme Corp. Antagonistes du récepteur p2x3 pour le traitement de la douleur
LT2419104T (lt) * 2009-04-13 2018-02-12 Theravance Biopharma R&D Ip, Llc 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (fr) 2010-02-02 2014-10-15 Novartis AG Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
RU2016107848A (ru) 2013-08-09 2017-09-15 Сантен Фармасьютикал Ко., Лтд. Способ получения производного 3,3-диметил-3,4-дигидро-1н-хиноксалин-2-она и промежуточное соединение для указанного способа получения

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
JPH111472A (ja) 1996-04-30 1999-01-06 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体及びそれを含有する医薬組成物
ES2234248T3 (es) * 1998-04-28 2005-06-16 Dainippon Pharmaceutical Co., Ltd. Derivados de 1-(1-sustituido-4-piperidinil) metil)-4-piperidina, procedimiento de produccion de estos; composiciones medicinales que contienen estos compuestos e intermediarios de estos compuestos.
BR9915013A (pt) 1998-11-03 2001-08-07 Basf Ag Composto, uso dos mesmos, processo para preparar os mesmos, droga, e, método para detecção in vitro para inibidores parp
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
JP2001122784A (ja) 1999-10-27 2001-05-08 Dainippon Pharmaceut Co Ltd １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬
US6552046B2 (en) * 2000-06-07 2003-04-22 Aryx Therapeutics Materials and methods for the treatment of gastroesophageal reflux disease
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
WO2004014895A1 (fr) 2002-08-05 2004-02-19 Eli Lilly And Company Aryl benzodiazepines substituees par de la piperazine
JP2006502180A (ja) * 2002-09-20 2006-01-19 ファイザー株式会社 ５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物
JP2004277318A (ja) * 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
JP2004277319A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
JP2004277320A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １，４−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物
PL1664036T3 (pl) 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound

Also Published As

Publication number Publication date
US10696656B2 (en) 2020-06-30
MX2007014762A (es) 2008-02-14
PL1899324T3 (pl) 2012-04-30
CY1112366T1 (el) 2015-12-09
IL186883A (en) 2013-03-24
EP1899324B1 (fr) 2011-11-30
WO2006127815A3 (fr) 2007-08-02
US20100249186A1 (en) 2010-09-30
CA2607280C (fr) 2013-09-17
NZ563068A (en) 2011-01-28
KR20080021045A (ko) 2008-03-06
US20170081313A1 (en) 2017-03-23
US10233172B2 (en) 2019-03-19
US20150183761A1 (en) 2015-07-02
JP5072111B2 (ja) 2012-11-14
BRPI0611202A2 (pt) 2010-08-24
JP2008542281A (ja) 2008-11-27
PT1899324E (pt) 2012-01-24
US20190152951A1 (en) 2019-05-23
US9428489B2 (en) 2016-08-30
US11254655B2 (en) 2022-02-22
HRP20120108T1 (en) 2012-02-29
US8143279B2 (en) 2012-03-27
ATE535523T1 (de) 2011-12-15
HRP20120108T2 (hr) 2012-03-31
ES2376115T3 (es) 2012-03-09
BRPI0611202B1 (pt) 2019-09-24
EA013240B1 (ru) 2010-04-30
AU2006250009B2 (en) 2012-03-08
EA200702612A1 (ru) 2008-06-30
AR057327A1 (es) 2007-11-28
AU2006250009A1 (en) 2006-11-30
US9975877B2 (en) 2018-05-22
JP2012197322A (ja) 2012-10-18
SI1899324T1 (sl) 2012-03-30
TWI388555B (zh) 2013-03-11
US20130273568A1 (en) 2013-10-17
US7759363B2 (en) 2010-07-20
PE20061446A1 (es) 2007-01-16
US20200283408A1 (en) 2020-09-10
BRPI0611202C1 (pt) 2021-05-25
WO2006127815A2 (fr) 2006-11-30
US20180237420A1 (en) 2018-08-23
EP1899324A2 (fr) 2008-03-19
BRPI0611202B8 (pt) 2019-09-24
CA2607280A1 (fr) 2006-11-30
US20060270652A1 (en) 2006-11-30
NO20076481L (no) 2007-12-17
US20220274957A1 (en) 2022-09-01
TW200716607A (en) 2007-05-01
MY147756A (en) 2013-01-15
US8377964B2 (en) 2013-02-19
KR101333280B1 (ko) 2013-11-28
IL186883A0 (en) 2008-02-09
HK1110980A1 (en) 2008-07-25
DK1899324T3 (da) 2012-02-13
US20090209582A1 (en) 2009-08-20
NO339658B1 (no) 2017-01-16

Similar Documents

Publication Publication Date Title
MA29541B1 (fr) Composes benzimidazole-carboxamide utilises comme agonistes du recepteur 5-ht4
MA28304A1 (fr) Derives d'arylaniline utilise comme agonistes des recepteurs beta2-adrenergiques
CY1119008T1 (el) Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα
MY155036A (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
WO2005121065A3 (fr) Agonistes des recepteurs $g(b)2-adrenergiques diaminiques
WO2006052889A3 (fr) Composes de quinolinone-carboxamide
MA27779A1 (fr) FORME CRISTALLINE D'AGONISTE DE RECEPTEUR β2 ADRENERGIQUE
DE602006019595D1 (de) Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
MA34767B1 (fr) Compositions et procédés pour la modulation de fxr
AP1542A (en) Glucocorticoid receptor modulators.
BRPI0519708A2 (pt) compostos de indazol-carboxamida
MA30556B1 (fr) COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
EA200800540A1 (ru) Карбоксамидные производные в качестве антагонистов мускариновых рецепторов
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
BR0104834A (pt) Moduladores de receptores de glucocorticóides
DE60120077D1 (de) Modulatoren des Glucocorticoid-Rezeptors
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.
DE602004024383D1 (de) Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
EA200701867A1 (ru) Хинолиноновые соединения в качестве агонистов рецептора 5-ht
MXPA05013256A (es) Derivados de 1-(alquilaminoalquil-pirolidin-/piperidinil) -2,2-difenilacetamida como antagonistas de receptores muscarinicos.
MY143574A (en) Carbamate compounds as 5-ht4 receptor agonists
MA33426B1 (fr) Formulations